Literature DB >> 23429919

Contributors to diffusion impairment in HIV-infected persons.

Matthew R Gingo1, Jiayan He, Catherine Wittman, Carl Fuhrman, Joseph K Leader, Cathy Kessinger, Lorrie Lucht, William A Slivka, Yingze Zhang, Deborah K McMahon, Frank C Sciurba, Alison Morris.   

Abstract

Abnormal diffusing capacity is common in HIV-infected individuals, including never smokers. Aetiologies for diffusing capacity impairment in HIV are not understood, particularly in those without a history of cigarette smoking. Our study was a cross-sectional analysis of 158 HIV-infected individuals without acute respiratory symptoms or infection with the aim to determine associations between a diffusing capacity of the lung for carbon monoxide (D(LCO)) % predicted and participant demographics, pulmonary spirometric measures (forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity), radiographic emphysema (fraction of lung voxels < -950 Hounsfield units), pulmonary vascular/cardiovascular disease (echocardiographic tricuspid regurgitant jet velocity, N-terminal pro-brain natriuretic peptide) and airway inflammation (induced sputum cell counts), stratified by history of smoking. The mean D(LCO) was 65.9% predicted, and 55 (34.8%) participants had a significantly reduced D(LCO) (<60% predicted). Lower D(LCO) % predicted in ever-smokers was associated with lower post-bronchodilator FEV1 % predicted (p<0.001) and greater radiographic emphysema (p=0.001). In never-smokers, mean±SD D(LCO) was 72.7±13.4% predicted, and D(LCO) correlated with post-bronchodilator FEV1 (p=0.02), sputum neutrophils (p=0.03) and sputum lymphocytes (p=0.009), but not radiographic emphysema. Airway obstruction, emphysema and inflammation influence D(LCO) in HIV. Never-smokers may have a unique phenotype of diffusing capacity impairment. The interaction of multiple factors may account for the pervasive nature of diffusing capacity impairment in HIV infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429919      PMCID: PMC4023348          DOI: 10.1183/09031936.00157712

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

1.  Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study.

Authors:  J V Fahy; H A Boushey; S C Lazarus; E A Mauger; R M Cherniack; V M Chinchilli; T J Craig; J M Drazen; J G Ford; J E Fish; E Israel; M Kraft; R F Lemanske; R J Martin; D McLean; S P Peters; C Sorkness; S J Szefler
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

2.  Automated lung segmentation in X-ray computed tomography: development and evaluation of a heuristic threshold-based scheme.

Authors:  Joseph K Leader; Bin Zheng; Robert M Rogers; Frank C Sciurba; Andrew Perez; Brian E Chapman; Sanjay Patel; Carl R Fuhrman; David Gur
Journal:  Acad Radiol       Date:  2003-11       Impact factor: 3.173

3.  Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava.

Authors:  B J Kircher; R B Himelman; N B Schiller
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

4.  Pulmonary function in non-insulin-dependent diabetes mellitus.

Authors:  M Marvisi; L Bartolini; P del Borrello; M Brianti; G Marani; A Guariglia; A Cuomo
Journal:  Respiration       Date:  2001       Impact factor: 3.580

5.  Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era.

Authors:  Alison Morris; Matthew R Gingo; M Patricia George; Lorrie Lucht; Cathy Kessinger; Vikas Singh; Maria Hillenbrand; Michelle Busch; Deborah McMahon; Karen A Norris; Hunter C Champion; Mark T Gladwin; Yingze Zhang; Chad Steele; Frank C Sciurba
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

6.  A computer program for stepwise logistic regression using maximum likelihood estimation.

Authors:  D W Hosmer; C Y Wang; I C Lin; S Lemeshow
Journal:  Comput Programs Biomed       Date:  1978-06

7.  Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998.

Authors:  Janice K Louie; Ling Chin Hsu; Dennis H Osmond; Mitchell H Katz; Sandra K Schwarcz
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

8.  Lung function abnormalities in patients infected with the human immunodeficiency virus with and without overt pneumonitis.

Authors:  R J Shaw; C Roussak; S M Forster; J R Harris; A J Pinching; D M Mitchell
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

9.  Reduced carbon monoxide transfer factor (TLCO) in human immunodeficiency virus type I (HIV-I) infection as a predictor for faster progression to AIDS.

Authors:  R B Nieman; J Fleming; R J Coker; J R Harris; D M Mitchell
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

10.  Pulmonary function in human immunodeficiency virus infection. A prospective 18-month study of serial lung function in 474 patients.

Authors:  D M Mitchell; J Fleming; A J Pinching; J R Harris; F M Moss; D Veale; R J Shaw
Journal:  Am Rev Respir Dis       Date:  1992-09
View more
  21 in total

1.  Decreased Lung Function and All-Cause Mortality in HIV-infected Individuals.

Authors:  Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2018-02

2.  Pulmonary Function in HIV-Infected Recreational Drug Users in the Era of Anti-Retroviral Therapy.

Authors:  Joseph A Simonetti; Matthew R Gingo; Lawrence Kingsley; Cathy Kessinger; Lorrie Lucht; Gk Balasubramani; Joseph K Leader; Laurence Huang; Ruth M Greenblatt; John Dermand; Eric C Kleerup; Alison Morris
Journal:  J AIDS Clin Res       Date:  2014-11

3.  Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort.

Authors:  Joseph K Leader; Kristina Crothers; Laurence Huang; Mark A King; Alison Morris; Bruce W Thompson; Sonia C Flores; Michael B Drummond; William N Rom; Philip T Diaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

4.  Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease.

Authors:  Lijia Cui; Lorrie Lucht; Laura Tipton; Matthew B Rogers; Adam Fitch; Cathy Kessinger; Danielle Camp; Lawrence Kingsley; Nicolas Leo; Ruth M Greenblatt; Serena Fong; Stephen Stone; John C Dermand; Eric C Kleerup; Laurence Huang; Alison Morris; Elodie Ghedin
Journal:  Am J Respir Crit Care Med       Date:  2015-04-15       Impact factor: 21.405

Review 5.  Heart-lung interaction via infection.

Authors:  Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2014-01

6.  Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease.

Authors:  Alison Morris; Meghan Fitzpatrick; Marnie Bertolet; Shulin Qin; Lawrence Kingsley; Nicolas Leo; Cathy Kessinger; Heather Michael; Deborah Mcmahon; Renee Weinman; Stephen Stone; Joseph K Leader; Eric Kleerup; Laurence Huang; Stephen R Wisniewski
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

Review 7.  Non-infectious Pulmonary Diseases and HIV.

Authors:  M Triplette; K Crothers; E F Attia
Journal:  Curr HIV/AIDS Rep       Date:  2016-06       Impact factor: 5.071

Review 8.  Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy.

Authors:  Meghan E Fitzpatrick; Ken M Kunisaki; Alison Morris
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

Review 9.  HIV-associated obstructive lung diseases: insights and implications for the clinician.

Authors:  M Bradley Drummond; Gregory D Kirk
Journal:  Lancet Respir Med       Date:  2014-05-13       Impact factor: 30.700

Review 10.  Maintaining lung health with longstanding HIV.

Authors:  Paul Collini; Alison Morris
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.